Obsidian Therapeutics, Inc. Common Stock (OBX) - Total Liabilities
Based on the latest financial reports, Obsidian Therapeutics, Inc. Common Stock (OBX) has total liabilities worth $346.33 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Obsidian Therapeutics, Inc. Common Stock liquidity resilience to evaluate the company's liquid asset resilience ratio.
Obsidian Therapeutics, Inc. Common Stock - Total Liabilities Trend (2024–2025)
This chart illustrates how Obsidian Therapeutics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see OBX total asset value.
Obsidian Therapeutics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Obsidian Therapeutics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SeAH Bestee
KO:001430
|
Korea | ₩2.05 Trillion |
|
Yutong Optical
SHE:300790
|
China | CN¥3.30 Billion |
|
Dorian LPG Ltd
NYSE:LPG
|
USA | $713.63 Million |
|
Zhejiang Sanwei Rubber Item Co
SHG:603033
|
China | CN¥7.83 Billion |
|
Yantai Changyu Pioneer Wine Co Ltd
SHE:000869
|
China | CN¥1.45 Billion |
|
Suofeiya Home Collection Co Ltd
SHE:002572
|
China | CN¥5.50 Billion |
|
Mercantile Bank Corporation
NASDAQ:MBWM
|
USA | $6.06 Billion |
|
Safety Insurance Group Inc
NASDAQ:SAFT
|
USA | $1.58 Billion |
Liability Composition Analysis (2024–2025)
This chart breaks down Obsidian Therapeutics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See OBX net asset quality score to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.21 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 4.94 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Obsidian Therapeutics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Obsidian Therapeutics, Inc. Common Stock (2024–2025)
The table below shows the annual total liabilities of Obsidian Therapeutics, Inc. Common Stock from 2024 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $354.62 Million | -0.98% |
| 2024-12-31 | $358.14 Million | -- |
About Obsidian Therapeutics, Inc. Common Stock
Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for advanced solid tumors, advanced melanoma, and relapsed refractory non-small cell lung cancer. It utilizes a proprietary Cytodriver technology platform de… Read more